Home › Research › Risk factors
Community-level Alzheimer’s Disease or Related Dementia’s 65+ Prevalence in Five New England States
Taylor Jansen, Nina M. Silverstein, Yan‐Jhu Su, Shan Qu, Mengshi Liu, Yan Lin, Qian Song, Elizabeth Dugan. Innovation in Aging, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Abstract An estimated two thirds of people living with Alzheimer’s disease or related dementias (ADRD) live and are cared for at home. For public health action and community programming to assist those living with ADRD, accurate disease rates must be known. The Healthy Aging Data Reports (HADR) (www.healthyagingdatareports.org) are a comprehensive tool to spur community and policy action as they calculate community-level prevalence of 38 chronic diseases for each community in a state. The present descriptive study will compare community and neighborhood-level 65+ prevalence of ADRD in five New England states: Connecticut (CT), Massachusetts (MA), Maine (ME), New Hampshire (NH), and Rhode Island (RI). Using Medicare Beneficiary Summary File (MBSF) (2020-2021), representative of 100% of traditional Medicare beneficiaries, small area estimation techniques were used to calculate age-sex adjusted community rates of ADRD and over 150 other health indicators. Results varied across states with NH reporting the lowest community rate of 65+ ADRD in the sample (5.41%) and CT reporting the highest (27.10%). CT and MA reported the largest range in 65+ ADRD (CT: 6.90-27.10%; MA: 6.69-25.54%) with the highest rate clusters located near the biggest cities, in urban areas (CT:13.11-27.10%; MA: 12.93-25.54%). Conversely, in Maine and NH, the highest rate clusters were found in rural areas (NH: 15.82-21.16%; ME: 15.33-18.98%). The 2025 HADR’s found geographic disparities in 65+ community-level ADRD across New England. Communities with high rates can be targeted for additional supports like caregiver support programming, adult day health centers, and educational programming on the prevention and treatment of ADRD.
What this study adds
Evidence grade: Low
This study describes how common Alzheimer's disease and related dementias are in communities across five New England states, using Medicare data. Reported effect size: 5.41%; 27.10%; 25.54%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jansen, T., Silverstein, N. M., Su, Y., Qu, S., Liu, M., Lin, Y., et al. (2025). Community-level Alzheimer’s Disease or Related Dementia’s 65+ Prevalence in Five New England States. Innovation in Aging. https://doi.org/10.1093/geroni/igaf122.2848
Vancouver
Jansen T, Silverstein NM, Su Y, Qu S, Liu M, Lin Y, et al. Community-level Alzheimer’s Disease or Related Dementia’s 65+ Prevalence in Five New England States. Innovation in Aging. 2025. doi:10.1093/geroni/igaf122.2848.
BibTeX
@article{jansen2025-29429fe2,
author = {Jansen, Taylor and Silverstein, Nina M. and Su, Yan‐Jhu and Qu, Shan and Liu, Mengshi and Lin, Yan and Song, Qian and Dugan, Elizabeth},
title = {{Community-level Alzheimer’s Disease or Related Dementia’s 65+ Prevalence in Five New England States}},
journal = {Innovation in Aging},
year = {2025},
doi = {10.1093/geroni/igaf122.2848},
url = {https://doi.org/10.1093/geroni/igaf122.2848}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results varied across states with NH reporting the lowest community rate of 65+ ADRD in the sample (5.41%) and CT reporting the highest (27.10%).
Why it matters
This study describes how common Alzheimer's disease and related dementias are in communities across five New England states, using Medicare data. It does not test any treatment, cure, or prevention, so it cannot say whether any approach works.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Effect size5.41%; 27.10%; 25.54%
- Evidence strengthLow
How this study scored 31/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Innovation in Aging) |
| Journal's citation record | 0 / 4 | Innovation in Aging: journal h-index 48 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Elizabeth Dugan: h-index 31 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Pennsylvania State University: institution h-index 1,397 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 31 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Risk factors from nearby years
Also tagged “prevalence”
1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.